HLA-B Locus in Japanese Patients with Anti-Epileptics and Allopurinol-Related Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
-
- Nahoko Kaniwa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Michiko Aihara
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Kayoko Matsunaga
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Masahiro Tohkin
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Kouichi Kurose
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Jun-ichi Sawada
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Hirokazu Furuya
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Yukitoshi Takahashi
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Masaaki Muramatsu
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Shigeru Kinoshita
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Masamichi Abe
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Hiroko Ikeda
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Mariko Kashiwagi
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Yixuan Song
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Mayumi Ueta
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Chie Sotozono
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Zenro Ikezawa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
-
- Ryuichi Hasegawa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-11 Kamiyoga, Setagaya-ku, Tokyo
書誌事項
- 公開日
- 2008-11
- DOI
-
- 10.2217/14622416.9.11.1617
- 公開者
- Informa UK Limited
この論文をさがす
説明
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Recently, strong associations of HLA-B*1502 and HLA-B*5801 with carbamazepine- and allopurinol-induced severe cutaneous adverse reactions were found in Han Chinese patients, respectively, but ethnic differences in the associations have been reported. The objective of this study is to clarify the involvement of HLA-B*1502 and HLA-B*5801 in Japanese SJS/TEN patients.HLA-B genotyping was performed on 58 Japanese SJS/TEN patients between July 2006 and April 2008 from multicenters in Japan.There were no HLA-B*1502 carriers among 58 SJS/TEN patients. This patient group included seven carbamazepine-related and 11 aromatic anti-epileptic agent-related SJS/TEN patients. In addition, there were five HLA-B*5801 carriers, which included four allopurinol-related SJS/TEN patients.While HLA-B*1502 is unlikely to be associated with carbamazepine-related or aromatic anti-epileptic agent-related SJS/TEN, HLA-B*5801 was significantly associated with allopurinol-related SJS/TEN in Japanese.
収録刊行物
-
- Pharmacogenomics
-
Pharmacogenomics 9 (11), 1617-1622, 2008-11
Informa UK Limited
